Cart
sales@molnova.com
Lumazine
CAS No. 487-21-8
Lumazine( 24-Dihydroxypteridine )
Catalog No. M19682 CAS No. 487-21-8
Lumazine is a new MALDI matrix for complex (phospho)lipid mixtures analysis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 50MG | 28 | In Stock |
|
| 100MG | 37 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 86 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLumazine
-
NoteResearch use only, not for human use.
-
Brief DescriptionLumazine is a new MALDI matrix for complex (phospho)lipid mixtures analysis.
-
DescriptionLumazine is a new MALDI matrix for complex (phospho)lipid mixtures analysis.
-
In Vitro——
-
In Vivo——
-
Synonyms24-Dihydroxypteridine
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number487-21-8
-
Formula Weight164.12
-
Molecular FormulaC6H4N4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESO=c1[nH]c2nccnc2c(=O)[nH]1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Cioffi N et al. Silver nanofractals: electrochemical synthesis XPS characterization and application in LDI-MS. Anal Bioanal Chem. 2009 Jul;394(5):1375-83.
molnova catalog
related products
-
(Phenylac-Tyr1,D-Arg...
JV-1-36 is a growth hormone-releasing hormone (GHRH) antagonist. JV-1-36 inhibits the production of reactive oxygen species in A549 lung cancer cells. JV-1-36 can be used to study the effect of GHRH antagonists in vitro .
-
1-Palmitoyl-2-Arachi...
1-Palmitoyl-2-Arachidonoyl-sn-glycero-3-PC (1-Palmitoyl-2-Arachidonoyl-sn-glycero-3-Phosphocholine) is a phospholipid found in biological membranes that contains palmitic acid (16:0) and arachidonic acid (20:0) in its structure. (16:0) and arachidonic acid (20:4) in its structure.
-
Valbenazine
A novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor; is approved for the treatment of tardive dyskinesia.
